Your Health, We Care
Release date: 2025-04-03 13:59:51 Recommended: 56
The effect of treatment is a key indicator for evaluating the drug.
According to the results of the phase III clinical trial, the median progression-free survival of patients using the drug reached 10.9 months, which was nearly 3 times higher than that of traditional chemotherapy regimens.
Imaging evaluation showed that about 65% of patients experienced a tumor volume reduction of more than 30% and an average extension of the duration of symptom remission to 8.5 months.
For the ALK gene rearrangement positive population, the objective response rate was 74%. After 6 months of treatment, the patient's performance status score improved by 58%, which was significantly better than other targeted therapy regimens. The precise drug use mode under the guidance of genetic testing has become an important prerequisite for improving the efficacy.
Among patients who continued to take the drug for 12 months, the incidence of adverse reactions above grade 3 was controlled within 28%. Common side effects, such as visual disturbances (19%) and gastrointestinal reactions (32%), were manageable and could be maintained through dose adjustment.
The cost of treatment is an important factor influencing medication decisions.
The drug costs about $6,900 per month and includes standard doses and routine monitoring. Compared with the traditional chemoradiotherapy comprehensive regimen, the annual treatment cost gap is reduced to less than 15%. Some medical centers offer installment payment options to reduce initial financial stress.
78% of major commercial insurance plans in the U.S. include reimbursement for the drug. Medicaid offers a 70%-85% fee waiver for patients who meet criteria for genetic testing. It is recommended to complete the pre-authorization application process prior to treatment.
Pharmaceutical companies have set up special funds to support families with annual incomes of less than $80,000, up to 80% of annual expenses. Nonprofit organizations regularly issue drug discount cards, and some pharmacies offer buy-and-give discounts, which can reduce the actual cost of payment to $2,100 per month.
In the era of precision medicine, multi-dimensional evaluation of treatment options is required. The individualized medication model guided by genetic testing, combined with a well-established financial assistance system, provides new possibilities for improving the prognosis of patients. When the care team and the patient make decisions together, they need to balance multiple factors such as clinical outcomes, quality of life, and affordability.
